[Coinfection with HIV and HCV: abacavir and ribavirine, why not?].

Abstract

A 48-year old male coinfected by human immunodeficiency virus and hepatitis C virus (HCV) genotype 3a. The patient was under clinically and virologically effective treatment with Trizivir (zidovudine, lamivudine and abacavir) when it was decided to initiate treatment for the chronic HCV infection with peginterferon and ribavirin. Should the ongoing antiretroviral treatment be adjusted?

• Authors: M E Valencia, V Moreno
• Journal: Revista clinica espanola (Rev Clin Esp) Vol. 212 Issue 1 Pg. 26-30 (Jan 2012) ISSN: 1578-1860 [Electronic] Spain
• Vernacular Title: Coinfección por VIH y VHC: abacavir y ribavirina, ¿por qué no?
• PMID: 21839993 (Publication Type: Case Reports, Journal Article)
• Copyright: Copyright © 2011 Elsevier España, S.L. All rights reserved.

Chemical References

• Anti-HIV Agents
• Antiviral Agents
• Dideoxynucleosides
• Drug Combinations
• abacavir, lamivudine, and zidovudine drug combination
• Lamivudine
• Ribavirin
• Zidovudine
• abacavir

Topics

• Anti-HIV Agents (therapeutic use)
• Antiviral Agents (therapeutic use)
• Coinfection (drug therapy)
• Dideoxynucleosides (therapeutic use)
• Drug Combinations
• Drug Interactions
• HIV Infections (complications, drug therapy)
• Hepatitis C, Chronic (complications, drug therapy)
• Humans
• Lamivudine (therapeutic use)
• Male
• Middle Aged
• Ribavirin (therapeutic use)
• Zidovudine (therapeutic use)